Резистентность к антиагрегантным препаратам: механизмы, роль коморбидности и других клинических факторов

Standard

Резистентность к антиагрегантным препаратам: механизмы, роль коморбидности и других клинических факторов. / Lukianets, K.; Pchelin, I.; Shishkin, A.; Volovnikova, V.; Droganova, A.

в: Kardiologija v Belarusi, Том 13, № 5, 2021, стр. 815-826.

Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование

BibTeX

@article{9d29d36ed33945b993af2a984162e234,

title = "Резистентность к антиагрегантным препаратам: механизмы, роль коморбидности и других клинических факторов",

abstract = "Acetylsalicylic acid (aspirin) and clopidogrel are the most widespread antiplatelet drugs used for secondary prevention of atherothrombotic events in patients with cardiovascular disease, including the dual antiplatelet therapy regimen. Considering the fact that the risk of atherothrombosis is directly related to the vital prognosis, the problem of the efficacy of antiplatelet therapy is one of the most relevant in cardiology. The issue of personalization of antiplatelet therapy, which still has minimal implications in real clinical practice, also deserves attention. In this review, we analyzed the recent data on aspirin and clopidogrel resistance. Possible mechanisms of this phenomenon are considered. The problems related to the definition of diagnostic criteria are discussed. The data on the comorbidity and other clinical factors are summarized.",

keywords = "Acetylsalicylic acid, Antiplatelet agents, Aspirin, Clopidogrel, Platelets, Resistance",

author = "K. Lukianets and I. Pchelin and A. Shishkin and V. Volovnikova and A. Droganova",

year = "2021",

doi = "10.34883/PI.2021.13.5.014",

language = "русский",

volume = "13",

pages = "815--826",

journal = "Кардиология в Беларуси",

issn = "2072-912X",

publisher = "Professionalnye Izdaniya",

number = "5",

}

RIS

TY - JOUR

T1 - Резистентность к антиагрегантным препаратам: механизмы, роль коморбидности и других клинических факторов

AU - Lukianets, K.

AU - Pchelin, I.

AU - Shishkin, A.

AU - Volovnikova, V.

AU - Droganova, A.

PY - 2021

Y1 - 2021

N2 - Acetylsalicylic acid (aspirin) and clopidogrel are the most widespread antiplatelet drugs used for secondary prevention of atherothrombotic events in patients with cardiovascular disease, including the dual antiplatelet therapy regimen. Considering the fact that the risk of atherothrombosis is directly related to the vital prognosis, the problem of the efficacy of antiplatelet therapy is one of the most relevant in cardiology. The issue of personalization of antiplatelet therapy, which still has minimal implications in real clinical practice, also deserves attention. In this review, we analyzed the recent data on aspirin and clopidogrel resistance. Possible mechanisms of this phenomenon are considered. The problems related to the definition of diagnostic criteria are discussed. The data on the comorbidity and other clinical factors are summarized.

AB - Acetylsalicylic acid (aspirin) and clopidogrel are the most widespread antiplatelet drugs used for secondary prevention of atherothrombotic events in patients with cardiovascular disease, including the dual antiplatelet therapy regimen. Considering the fact that the risk of atherothrombosis is directly related to the vital prognosis, the problem of the efficacy of antiplatelet therapy is one of the most relevant in cardiology. The issue of personalization of antiplatelet therapy, which still has minimal implications in real clinical practice, also deserves attention. In this review, we analyzed the recent data on aspirin and clopidogrel resistance. Possible mechanisms of this phenomenon are considered. The problems related to the definition of diagnostic criteria are discussed. The data on the comorbidity and other clinical factors are summarized.

KW - Acetylsalicylic acid

KW - Antiplatelet agents

KW - Aspirin

KW - Clopidogrel

KW - Platelets

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85120892115&partnerID=8YFLogxK

U2 - 10.34883/PI.2021.13.5.014

DO - 10.34883/PI.2021.13.5.014

M3 - Обзорная статья

AN - SCOPUS:85120892115

VL - 13

SP - 815

EP - 826

JO - Кардиология в Беларуси

JF - Кардиология в Беларуси

SN - 2072-912X

IS - 5

ER -

ID: 90570274